MDGL vs. IMVT

Last updated Apr 1, 2026

Compare and contrast key facts about Madrigal Pharmaceuticals, Inc. (MDGL) and Immunovant, Inc. (IMVT).

Performance

MDGL vs. IMVT - Performance Comparison

The chart below illustrates the hypothetical performance of a $10,000 investment in Madrigal Pharmaceuticals, Inc. (MDGL) and Immunovant, Inc. (IMVT). The values are adjusted to include any dividend payments, if applicable.

MDGL vs. IMVT - Yearly Performance Comparison

	2026 (YTD)	2025	2024	2023	2022	2021	2020	2019
MDGL Madrigal Pharmaceuticals, Inc.	-10.11%	88.72%	33.36%	-20.28%	242.52%	-23.77%	22.02%	2.61%
IMVT Immunovant, Inc.	-2.28%	2.62%	-41.21%	137.35%	108.33%	-81.55%	191.05%	-0.69%

Fundamentals

Market Cap MDGL : $11.74B IMVT : $4.51B
EPS MDGL : -$12.88 IMVT : -$2.65
PB Ratio MDGL : 19.49 IMVT : 4.57
Total Revenue (TTM) MDGL : $958.40M IMVT : $0.00
Gross Profit (TTM) MDGL : $902.26M IMVT : -$105.00K
EBITDA (TTM) MDGL : -$300.10M IMVT : -$372.49M

Returns By Period

In the year-to-date period, MDGL achieves a -10.11% return, which is significantly lower than IMVT's -2.28% return.

MDGL

• 1D: 3.59%
• 1M: 21.17%
• YTD: -10.11%
• 6M: 14.13%
• 1Y: 58.04%
• 3Y*: 29.28%
• 5Y*: 34.58%
• 10Y*: 50.55%

IMVT

• 1D: 5.48%
• 1M: -10.42%
• YTD: -2.28%
• 6M: 54.09%
• 1Y: 45.35%
• 3Y*: 17.00%
• 5Y*: 8.07%
• 10Y*: —

*Multi-year figures are annualized to reflect compound growth (CAGR)

Return for Risk

MDGL vs. IMVT — Risk / Return Rank

Compare risk-adjusted metric ranks to identify better-performing investments over the past 12 months.

MDGL

MDGL Risk / Return Rank: 78
MDGL Sharpe Ratio Rank: 81
MDGL Sortino Ratio Rank: 80
MDGL Omega Ratio Rank: 75
MDGL Calmar Ratio Rank: 78
MDGL Martin Ratio Rank: 75

IMVT

IMVT Risk / Return Rank: 69
IMVT Sharpe Ratio Rank: 69
IMVT Sortino Ratio Rank: 69
IMVT Omega Ratio Rank: 63
IMVT Calmar Ratio Rank: 72
IMVT Martin Ratio Rank: 70

The rank (0–100) shows how this investment's returns compare to the risk taken. Higher = better. Based on the past 12 months of data, combining Sharpe, Sortino, and other metrics used by quantitative funds and institutional investors.

MDGL vs. IMVT - Risk-Adjusted Trends Comparison

This table presents a comparison of risk-adjusted performance metrics for Madrigal Pharmaceuticals, Inc. (MDGL) and Immunovant, Inc. (IMVT). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.

	MDGL	IMVT	Difference
Sharpe ratio Return per unit of total volatility	1.28	0.82	+0.46
Sortino ratio Return per unit of downside risk	2.09	1.55	+0.54
Omega ratio Gain probability vs. loss probability	1.24	1.17	+0.07
Calmar ratio Return relative to maximum drawdown	2.03	1.59	+0.44
Martin ratio Return relative to average drawdown	4.45	3.36	+1.09
Data is calculated on a 1-year rolling basis and updated daily. The trend shows the change in the indicator over the past month.

MDGL vs. IMVT - Sharpe Ratio Comparison

The current MDGL Sharpe Ratio is 1.28, which is higher than the IMVT Sharpe Ratio of 0.82. The chart below compares the historical Sharpe Ratios of MDGL and IMVT, offering insights into how both investments have performed under varying market conditions. These values are calculated using daily returns over the previous 12 months.

Sharpe Ratios by Period

	MDGL	IMVT	Difference
Sharpe Ratio (1Y) Calculated over the trailing 1-year period	1.28	0.82	+0.46
Sharpe Ratio (5Y) Calculated over the trailing 5-year period	0.26	0.11	+0.15
Sharpe Ratio (10Y) Calculated over the trailing 10-year period	0.42	—	—
Sharpe Ratio (All Time) Calculated using the full available price history	0.03	0.09	-0.07

Correlation

The correlation between MDGL and IMVT is 0.34, which is considered to be low. This implies their price changes are not closely related. A low correlation is generally favorable for portfolio diversification, as it helps to reduce overall risk by spreading it across multiple assets with different performance patterns.

Dividends

MDGL vs. IMVT - Dividend Comparison

Neither MDGL nor IMVT has paid dividends to shareholders.

Tickers have no history of dividend payments

Drawdowns

MDGL vs. IMVT - Drawdown Comparison

The maximum MDGL drawdown since its inception was -98.40%, which is greater than IMVT's maximum drawdown of -93.59%. Use the drawdown chart below to compare losses from any high point for MDGL and IMVT.

Drawdown Indicators

	MDGL	IMVT	Difference
Max Drawdown Largest peak-to-trough decline	-98.40%	-93.59%	-4.81%
Max Drawdown (1Y) Largest decline over 1 year	-29.36%	-20.98%	-8.38%
Max Drawdown (5Y) Largest decline over 5 years	-61.41%	-79.94%	+18.53%
Max Drawdown (10Y) Largest decline over 10 years	-82.19%	—	—
Current Drawdown Current decline from peak	-13.16%	-52.87%	+39.71%
Average Drawdown Average peak-to-trough decline	-58.97%	-54.24%	-4.73%
Ulcer Index Depth and duration of drawdowns from previous peaks	13.41%	10.49%	+2.92%

Volatility

MDGL vs. IMVT - Volatility Comparison

The current volatility for Madrigal Pharmaceuticals, Inc. (MDGL) is 13.96%, while Immunovant, Inc. (IMVT) has a volatility of 14.73%. This indicates that MDGL experiences smaller price fluctuations and is considered to be less risky than IMVT based on this measure. The chart below showcases a comparison of their rolling one-month volatility.

Volatility by Period

	MDGL	IMVT	Difference
Volatility (1M) Calculated over the trailing 1-month period	13.96%	14.73%	-0.77%
Volatility (6M) Calculated over the trailing 6-month period	32.63%	37.06%	-4.43%
Volatility (1Y) Calculated over the trailing 1-year period	45.66%	56.17%	-10.51%
Volatility (5Y) Calculated over the trailing 5-year period, annualized	133.38%	75.18%	+58.20%
Volatility (10Y) Calculated over the trailing 10-year period, annualized	119.65%	77.70%	+41.95%

Financials